I first became acquainted with the African proverb, “If you want to go fast, go alone. If you want to go far, go together,” during the most clinically challenging year of my graduate medical education: PGY-4, or the first year of a hematology/medical oncology fellowship. During simultaneous learning of the basics of chemotherapy and fighting off yet another wave of COVID-19, I also sought mentors in hematology and oncology to guide the development of my research pursuits. Luckily, I matched with 3 superior mentors and sponsors during my fellowship; however, this is not the case for every trainee. According to a survey of oncology trainees and early-career faculty (n = 306), respondents who were underrepresented in medicine (n = 64) were less likely to have a primary mentor compared with those who were not underrepresented in medicine (n = 242), at 66% vs 80%, respectively (P = .015).

 Now that I have completed my fellowship, I hope to share my reflections on the benefits, challenges, and critical elements of effective mentorship in hematology/oncology.

Although many benefits of mentorship have been reviewed, such as transitioning through traditional paths into academic practice, private practice, or drug development, the intangible products of mentorship are equally, if not more, valuable.

 Trainees must balance competing demands during hematology/oncology fellowship, varying from knowledge streams that consistently change to intricacies in patient populations and clinical trial design. It is often the mentor to whom a trainee turns for guidance when our field’s algorithmic recommendations cannot be routinely followed. For example, one mentor/ sponsor’s real-world experiences in various clinical settings, including academic, hybrid, and private practice, yielded invaluable insights that cannot be found online or through formal recruitment avenues. Without her guidance, my job search would have been much more complex.

Despite the various tangible benefits of mentorship, some challenges are also worth noting. Time is by far the most limiting factor. However, other difficulties may weigh into any mentor-mentee relationship, such as overcommitting, ghosting, and even backstabbing on the mentee’s part.

 Some strategies that might overcome these missteps include clearly stating one’s career goals, embracing failure as an inevitable part of growth, and remaining open to longitudinal feedback.

 Additionally, mentees might not only rely on a single mentor to propel their success but obtain multiple connections that serve various roles, including professional coaches, sponsors, and connectors.

 Looking outside one’s institution also yields multiplicative benefits for networking and connecting.

Mentoring and mentorship strategies will vary based on the mentor-mentee dyad. Throughout my fellowship, I have found the following methods particularly helpful:

Hematology and oncology are busy in terms of the complexity of patients seen and the emotional intensity required to practice. It is imperative that any trainee seeking mentorship or other career advice schedule such conversations well in advance. One of my mentors and sponsors serves in numerous institutional, national, and international roles, necessitating his constant availability outside working hours. We ensured adequate face-to-face time by scheduling bimonthly check-in meetings before deadlines and other pressing issues.

2. Show Up (to Clinic, Didactics, Conferences)

As the saying goes, half of life is about showing up. The hematology/oncology fellowship is a particularly challenging training period due to the lack of many of the fields’ subspecialty concepts being taught in medical school or residency. Although the clinical demands of fellowship can be trying, it is important to prioritize yourself and your career success by being present for as many educational and networking opportunities as time (and stress) permit. By attending various diseasefocused clinics, nearly every didactic session offered by my fellowship, and local, national, and international conferences, I have been fortunate to meet multiple mentors and sponsors among general and disease-specific oncology organizations. These individuals remain precious to me personally and my career growth.

3. Promote Those in Earlier Stages Than Yourself

Fellows must remember that, despite their own need for mentorship, they too can serve as mentors and sponsors for trainees in earlier stages than themselves. Indeed, elements of the “hidden curriculum” demonstrated by fellows often have downstream effects that manifest later in the careers of other trainees.

 During my chief fellowship year, I helped formalize a disease-focused working group that produced several research initiatives and served as a safe space within the complex graduate medical education network to discuss concerns, anxieties, and other pieces of advice. This community continues to be bolstered to this day, and I am both proud and nostalgic as I leave it behind.

Ralph Waldo Emerson defined success as leaving “the world a bit better” and this maxim applies to both mentors and mentees. Whether demonstrating this example in the clinic with patients or on rounds with mentees, the hematology/oncology clinician must leave a lasting example for those around them. Indeed, many of us (me included) naturally gravitate to these types of practitioners, launching us toward the hematology/ oncology training journey. As my training ends, I hope we all pledge to leave the best lasting examples we can.

Samuel A. Kareff, MD, MPH, is a medical oncologist and hematololgist at Baptist Health in Boca Raton, Florida. He was formerly the outgoing chief fellow of hematology and medical oncology at the University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital in Miami, Florida. 

Idossa D, Velazquez AI, Horiguchi M, et al. Mentorship experiences are not all the same: a survey study of oncology trainees and early-career faculty. 

. 2023;19(9):808-818. doi:10.1200/OP.22.00643

LaCasce A, Graff S, Gao J, Close J, Boulmay B. Preparing fellows for graduation: perspectives on career guidance. 

. 2019;39:609- 614. doi:10.1200/EDBK_242603

Vaughn V, Saint S, Chopra V. Mentee missteps: tales from the academic trenches. 

. 2017;317(5):475-476. doi:10.1001/jama.2016.12384

Chopra V, Arora VM, Saint S. Will you be my mentor? four archetypes to help mentees succeed in academic medicine. 

. 2018;178(2):175- 176. doi:10.1001/jamainternmed.2017.6537

Lawrence C, Mhlaba T, Stewart KA, Moletsane R, Gaede B, Moshabela M. The hidden curricula of medical education: a scoping review. 

. 2018;93(4):648-656. doi:10.1097/ACM.0000000000002004

Articles

Mentorship in hematology/oncology is crucial for navigating the complexities of the field, offering both tangible and intangible benefits. Effective mentorship can guide trainees through career transitions and provide invaluable real-world insights. However, challenges such as time constraints and potential missteps in mentor-mentee relationships exist. Strategies for successful mentorship include setting regular meetings, attending educational events, and fostering a supportive community. Mentors and mentees should aim to leave a lasting positive impact, promoting growth and success for themselves and others in the field.

Samuel A. Kareff, MD, MPH, shares his reflections on the benefits, challenges, and critical elements of effective mentorship in hematology/oncology.

The Importance of Hematology/Medical Oncology Fellowship

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Samuel A. Kareff, MD, MPH, about the intersections between early-phase clinical research and meaningful mentorship experiences during oncology/hematology fellowship. Dr Kareff is a medical oncologist and hematologist at the Eugene M. and Christine E. Lynn Cancer Institute, part of Baptist Health, in Boca Raton, Florida. He formerly served as chief fellow during his hematology/medical oncology fellowship at the University of Miami Sylvester Comprehensive Cancer Center in Florida.

In our exclusive interview, Dr Kareff discussed the rationale for and design of a proposed phase 1 clinical trial investigating the oncolytic virus SVV-001 in combination with nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with neuroendocrine carcinoma or neuroendocrine tumors. He also shared advice from his fellowship experience and emphasized how seeking out effective mentors can prepare fellows for the next steps in their careers.

That’s all we have for today! Thank you for listening to this episode of 

. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

 is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Podcasts

Dr Kareff discusses the intersections between early-phase clinical research and meaningful mentorship experiences during oncology/hematology fellowship.

Phase 1 Trials Provide Oncology Fellows With Valuable Clinical Research Experience: With Samuel A. Kareff, MD, MPH

Dr Kareff on the Utility of ADCs in NSCLC

Samuel Kareff, MD, MPH, chief fellow, Hematology/Oncology, University of Miami, Sylvester Comprehensive Cancer Center, Jackson Memorial Hospital, discusses key takeaways from an 

® workshop he participated in that focused on the treatment of patients with non–small cell lung cancer (NSCLC).

The workshop provided an insightful overview of both established and emerging antibody-drug conjugates (ADCs) within the realm of NSCLC, Kareff begins. One of the most notable aspects of such workshops is the opportunity they afford to delve into preliminary and early-phase data preceding larger phase 3 trials, he elucidates. This learning experience aids oncologists in grappling with the significance of ADCs, positioning this class of drugs as a pivotal component of future oncological approaches, he says. Furthermore, these types of workshops facilitate a comprehensive exploration of the identification of specific patient cohorts poised to benefit from these novel targeted therapies, an aspect laden with excitement, Kareff notes.

In this era characterized by precision oncology, the identification of new therapeutic targets holds a large amount of promise, furnishing both prognostic and predictive insights for distinct patient subgroups, Kareff relays. Although the focus remained primarily on NSCLC during the workshop, a plethora of agents targeting intriguing receptors, such as HER2, emerged, he expands. These agents are either currently employed in NSCLC, are under investigation in this disease, or boast commendable efficacy records in diseases beyond lung cancer, Kareff explains.

Moreover, witnessing the clinical development of these agents and discerning their promising signals in early-phase trials is profoundly encouraging, he continues. The observed success with ADCs thus far allows for speculation regarding their sustained efficacy in larger phase 3 trials, paving the way for continued advancements in NSCLC management, Kareff reports. Such insights underscore the intricate dynamic and nature of oncological research, and these developments have fueled optimism for improved treatment outcomes in NSCLC and beyond, he concludes.

Videos

Samuel Kareff, MD, MPH, discusses the treatment of patients with non–small cell lung cancer.